Theresa Bach
Nurse Practitioner · Oklahoma City, OKNPI 1538682463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 270 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,935, 2.2 times the $873 reported in 2022. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$846
- AbbVie$558
- Neurocrine Biosciences, Inc.$445
- SK Life Science, Inc.$441
- Argenx US, Inc.$438
- Pfizer$320
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,780100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 46 | $846 |
| AbbVie | 24 | $558 |
| Neurocrine Biosciences, Inc. | 20 | $445 |
| SK Life Science, Inc. | 21 | $441 |
| Argenx US, Inc. | 18 | $438 |
| Pfizer | 22 | $320 |
| Teva Pharmaceuticals USA, Inc. | 11 | $319 |
| AstraZeneca | 14 | $298 |
| Eisai Inc. | 10 | $231 |
| Genentech USA, Inc. | 7 | $164 |
| CSL Behring | 7 | $163 |
| Tanabe Pharma America, Inc. | 7 | $152 |
| Lilly USA, LLC | 8 | $151 |
| Catalyst Pharmaceuticals, Inc. | 5 | $119 |
| Kyowa Kirin, Inc. | 5 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $112 |
| Corium, LLC | 4 | $102 |
| TG Therapeutics, Inc. | 4 | $102 |
| Amgen | 4 | $73 |
| Vanda Pharmaceuticals Inc. | 2 | $72 |
| Avion Pharmaceuticals | 3 | $71 |
| Lundbeck LLC | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Johnson & Johnson | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Bristol Myers Squibb | 2 | $36 |
| Livanova USA, Inc. | 1 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Biogen | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $14 |
| Abbott | 1 | $13 |
How this compares
$5,780 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 28 | $33,007 |
| UbrelvyUbrogepant | 20 | $24,774 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $14,893 |
| Emgality PenGalcanezumab-Gnlm | 13 | $8,914 |
| Memantine Hcl | 98 | $3,017 |
| Rasagiline Mesylate | 13 | $2,825 |
| Gabapentin | 82 | $2,355 |
| Levetiracetam | 89 | $2,156 |
| Lacosamide | 11 | $1,448 |
| Ropinirole Hcl | 50 | $1,026 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 13 | $913 |
| Atorvastatin Calcium | 41 | $867 |
| Divalproex Sodium | 29 | $851 |
| Primidone | 48 | $841 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $320 | $33,00728 claims |
| AbbVieUbrelvy | $558 | $24,77420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Oklahoma City
- Sara GoreOklahoma City$52K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Janelle WagnerOklahoma City$13K
- Stefanie RollinsOklahoma City$13K
- Lacey CampbellOklahoma City$13K
- Stacey Waggoner FisherOklahoma City$9K
- Karie StewartOklahoma City$9K
- Lori CraigOklahoma City$8K
- Jennifer LewisOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.